Universidad Autonoma de Nuevo Leon
Also known as: Carlos A Acosta-Olivo | Departamento de Oftalmologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez | Department of Pharmacology and Toxicology of the Faculty of Medicine of the U.A.N.L | Endocrinology, University Hospital, Universidad Autonoma de Nuevo Leon | Erik Ramirez Lopez | Facultad de Medicina y Hospital Universitario Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon | Hospital Universitario Dr. Jose E. Gonzalez | Hospital Universitario "Dr. Jose Eleuterio Gonzalez" | Hospital Universitario Dr. Jose Eleuterio Gonzalez | Hospital Universitario ¨Dr. José Eleuterio González | Hospital Universitario "Dr. José Eleuterio González" | Hospital Universitario Dr. José Eleuterio González | Hospital Universitario "Dr. Jose Eleuterio Gonzalez, UANL | Hospital Universitario "Dr. Jose Eleuterio Gonzalez", UANL | Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León | Hospital Universitario J. Eleuterio González | Hospital Universitario Jose E Gonzalez | Hospital Universitario, Universidad Autonoma de Nuevo Leon | Posgrado De Periodoncia, Universidad autónoma de Nuevo León | Servicio de endocrinología Hospital Univertsitario, UANL | Servicio de Hematología Hospital Universitario "Dr. José Eleuterio Gonzalez" | UANL | UANL, Pharmacology and toxicology department | Universidad Autonoma de Nuevo Leon | Universidad Autónoma de Nuevo León | Universidad Autónoma de Nuevo León, Centro Universitario de Salud, Campus de la Salud | Universidad Autónoma de Nuevo León, Facultad de Medicina | UNIVERSIDAD AUTONOMA DE NUEVO LEON, School of Medicine, Department of Pediatrics | University Hospital "Dr. José Eleuterio González", Universidad Autonoma de Nuevo León (U.A.N.L.)
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2004Last known activity
Mar 3, 2025
Timeline
1930s
- Jan 1, 1933
Universidad Autonoma de Nuevo Leon— Founded
Drugs by trial phase (90 distinct, 86 trials)
Phase 4 (11 own, 0 via acquisition)
Phase 3 (15 own, 0 via acquisition)
Phase 2 (37 own, 0 via acquisition)
Phase 1 (13 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
- Anemia, Megaloblastic
- Anemia, Pernicious
- Anxiety Disorders
- Asthma
- Avitaminosis
- Blood Loss, Surgical
- Burns
- Bursitis
- Cerebral Palsy
- Chikungunya Fever
- Coronavirus Infections
- Dementia
- Diabetes Mellitus
- Disease
- Fasciitis
- Fasciitis, Plantar
- Fibromyalgia
- Graft vs Host Disease
- Hemolysis
- Hemorrhage
- Hodgkin Disease
- Hyperglycemia
- Hypothyroidism
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Metabolic Syndrome
- Motor Neuron Disease
- Myofascial Pain Syndromes
- Osteoarthritis
- Osteoarthritis, Knee
- Paralysis
- Patellofemoral Pain Syndrome
- Pneumonia
- Postpartum Hemorrhage
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Purpura, Thrombotic Thrombocytopenic
- Sclerosis
- Severe Acute Respiratory Syndrome
- Sleep Wake Disorders
- Somatoform Disorders
- Syndrome
- Thrombocytopenia
- Thrombosis
- Vitamin D Deficiency
Recent trials (50)
- NCT06758375Lead sponsorPhase 2Mar 3, 2025
- NCT06758375Sponsor investigatorPhase 2Mar 3, 2025
- NCT06904599Sponsor investigatorPhase 2Feb 1, 2025
- NCT06904599Lead sponsorPhase 2Feb 1, 2025
- NCT06886074Lead sponsorPhase 2Jan 2, 2025
- NCT06886074Sponsor investigatorPhase 2Jan 2, 2025
- NCT07039877Sponsor investigatorPhase 2Jan 2, 2025
- NCT07039877Lead sponsorPhase 2Jan 2, 2025
- NCT05638763Sponsor investigatorPhase 2Nov 30, 2024
- NCT05638763Lead sponsorPhase 2Nov 30, 2024
- NCT05638763Reponsible party - principal investigatorPhase 2Nov 30, 2024
- NCT06861478Lead sponsorPhase 2Oct 20, 2024
- NCT06861478Sponsor investigatorPhase 2Oct 20, 2024
- NCT06564805Lead sponsorN/AAug 20, 2024
- NCT06564805Sponsor investigatorN/AAug 20, 2024
Details
- Founded
- San Nicolás de los Garza, Nuevo León, MX Jan 1, 1933
- Last known activity
- Mar 3, 2025